Overview
Clinical Study Of Pegaptanib Sodium (EYE001) For Wet-Type Age-Related Macular Degeneration
Status:
Completed
Completed
Trial end date:
2008-11-01
2008-11-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
This study will examine the safety and efficacy of pegaptanib sodium in Japanese patients with wet-type age-related macular degeneration (AMD), who benefit further treatment and who want to continue the treatment after completion of the preceding study (A5751010).Phase:
Phase 2Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Pfizer
Criteria
Inclusion Criteria:- After completion of the preceding study (A5751010)
Exclusion Criteria:
- Serious heart, kidney and/or liver disease
- Diabetic retinopathy